Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17409868 | 0.80 | PIK3CD (0.44) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL28793917 | 0.77 | NUDT1 (0.51) | NUDT1PIK3CDPIK3CAPIK3CBBRD4 | |
| SCHEMBL29487195 | 0.75 | XDH (0.53) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL2619223 | 0.75 | CHEK1 (0.47) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL29705496 | 0.75 | NUDT1 (0.53) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL290117 | 0.75 | NOS1 (0.47) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL2112472 | 0.75 | PIK3CD (0.46) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL29506132 | 0.75 | NOS1 (0.47) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL21855766 | 0.75 | PIK3CD (0.46) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL1835481 | 0.75 | XDH (0.53) | NUDT1PIK3CDPIK3CAPIK3CBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131897-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3131896-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-3122741-B1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-06-06 | — | — | EP | disclosed |
| US-9969724-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9951063-B2 | 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9808445-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170129880-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME LLC | 2017-05-11 | — | — | US | disclosed |
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| US-20170027916-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-02 | — | — | US | disclosed |
| EP-3122741-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129880-A1 | FACTOR IXa INHIBITORS | F9, F12, TFPI | NUDT1 2924/4885PIK3CD 4013/4885PIK3CA 2677/4885 |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | NUDT1 2478/4885PIK3CD 2624/4885PIK3CA 3095/4885 |
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | CXCR3, CXCR1, CXCR2 | NUDT1 1928/4885PIK3CD 1543/4885PIK3CA 1309/4885 |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | NUDT1 2478/4885PIK3CD 2624/4885PIK3CA 3095/4885 |
| US-20170027916-A1 | FACTOR IXa INHIBITORS | F9, F12, TFPI | NUDT1 2924/4885PIK3CD 4013/4885PIK3CA 2677/4885 |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | NUDT1 1963/4885PIK3CD 2692/4885PIK3CA 2696/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | NUDT1 2216/4885PIK3CD 2145/4885PIK3CA 1861/4885 |
| US-20120277150-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | GPR119, GPR27, GPR65 | NUDT1 2599/4885PIK3CD 2665/4885PIK3CA 3176/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | NUDT1 4203/4885PIK3CD 2424/4885PIK3CA 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.